1202055-32-0 Usage
Uses
Used in Cancer Therapy:
NMS-P715 is used as an anti-cancer agent for its ability to block the growth and survival of cancer cells by inhibiting PP2A activity. It has shown promising effects in preclinical studies and has the potential to be further developed as a cancer therapy.
Used in Enhancing Chemotherapy Efficacy:
NMS-P715 is used as an enhancer of the anti-tumor effects of other chemotherapy drugs. It has been found to overcome drug resistance in cancer cells, making it a valuable addition to existing cancer treatment regimens.
Used in Drug Safety and Toxicity Studies:
NMS-P715 has demonstrated a good safety profile and low toxicity in animal studies, making it a potential candidate for further development and testing in the field of drug safety and toxicity research.
Check Digit Verification of cas no
The CAS Registry Mumber 1202055-32-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,2,0,5 and 5 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1202055-32:
(9*1)+(8*2)+(7*0)+(6*2)+(5*0)+(4*5)+(3*5)+(2*3)+(1*2)=80
80 % 10 = 0
So 1202055-32-0 is a valid CAS Registry Number.
1202055-32-0Relevant articles and documents
Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors
Caldarelli, Marina,Angiolini, Mauro,Disingrini, Teresa,Donati, Daniele,Guanci, Marco,Nuvoloni, Stefano,Posteri, Helena,Quartieri, Francesca,Silvagni, Marco,Colombo, Riccardo
, p. 4507 - 4511 (2011/09/12)
The synthesis and SAR of a series of novel pyrazolo-quinazolines as potent and selective MPS1 inhibitors are reported. We describe the optimization of the initial hit, identified by screening the internal library collection, into an orally available, potent and selective MPS1 inhibitor.
